"""Experimental Validation & Testing Framework for Pyrene Compounds.

Enables:
- Biochemical assay planning & prediction
- Cell-based apoptosis assay design
- Selectivity screening panel setup
- Combination efficacy prediction
- Pediatric PK/PD modeling
- IND-enabling studies planning
- Publication-ready data formatting
"""

from typing import List, Dict, Optional, Tuple
from dataclasses import dataclass
from enum import Enum
import json

@dataclass
class BiochemicalAssay:
    """Design of a biochemical binding assay."""
    assay_id: str
    compound_id: str
    target_protein: str
    method: str  # SPR, ITC, FluorPol, HTRF
    predicted_kd: float  # nanomolar
    confidence: float  # 0-1
    expected_duration: str
    resource_requirements: Dict

@dataclass
class CellAssay:
    """Design of a cell-based apoptosis assay."""
    assay_id: str
    compound_id: str
    mechanism: str  # INTRINSIC, EXTRINSIC, etc.
    cell_line: str
    apoptosis_readout: str  # Caspase3, Annexin V, PI staining
    expected_ec50: float  # nanomolar
    expected_efficacy: float  # % apoptosis at 10µM
    duration_hours: int
    animal_ethics: bool  # Pediatric consideration

@dataclass
class SelectivityScreen:
    """Off-target selectivity screening design."""
    screen_id: str
    compound_id: str
    panel_size: int  # Number of off-targets
    priority_targets: List[str]
    expected_selectivity_ratio: float  # Primary/off-target binding
    concern_flags: List[str]  # Known risk areas

@dataclass
class FormulationStrategy:
    """Pediatric-optimized formulation strategy."""
    compound_id: str
    formulation_type: str  # Solution, suspension, capsule, liquid
    target_age_group: str  # pediatric group
    volume_per_dose: float  # mL
    taste_masking: bool
    stability_requirement: str  # Room temp, refrigerated
    excipient_safety: float  # 0-1 pediatric safety

class AssayType(Enum):
    """Types of biochemical assays."""
    SPR = "surface_plasmon_resonance"  # Real-time kinetics
    ITC = "isothermal_titration_calorimetry"  # Thermodynamics
    FLUORPOL = "fluorescence_polarization"  # High-throughput
    HTRF = "homogeneous_time_resolved_fluorescence"  # HTRF assay
    ELISA = "enzyme_linked_immunosorbent"  # Sandwich assay
    BIOLAYER = "biolayer_interferometry"  # Label-free kinetics

class CellLine(Enum):
    """Recommended cell lines by target."""
    JURKAT = "jurkat"  # T-cell lymphoma (FAS model)
    RAJI = "raji"  # B-cell lymphoma (BCL2 model)
    MOLT4 = "molt4"  # T-ALL (caspase model)
    U937 = "u937"  # Myeloid cells (general apoptosis)
    HEK293 = "hek293"  # General mammalian
    SHSY5Y = "sh_sy5y"  # Neuroblastoma (pediatric solid)

class PyrenePediatricValidator:
    """Validates pyrene compounds for pediatric use."""

    def __init__(self):
        self.biochemical_assays = []
        self.cell_assays = []
        self.selectivity_screens = []
        self.formulation_strategies = []
        self.ind_requirements = self._load_ind_requirements()
        self.pediatric_standards = self._load_pediatric_standards()

    def _load_ind_requirements(self) -> Dict:
        """Load FDA IND application requirements."""
        return {
            'chemistry_manufacturing': {
                'structure_confirmation': ['NMR', 'MS', 'HPLC'],
                'purity_requirement': 0.98,  # 98%+
                'manufacturing_process': 'Fully described',
                'stability_data': '12+ months',
                'cmc_studies': 'Required for IND',
            },
            'pharmacology_toxicology': {
                'in_vitro_tox': 'Primary requirement',
                'genotoxicity': 'AMES, micronucleus',
                'acute_tox': 'Rodent (single dose)',
                'subchronic_tox': 'Rodent (14 or 28-day)',
                'reproductive_tox': 'Segment I/II as needed',
                'special_tox': 'Target organ studies',
            },
            'pharmacology_primary': {
                'mechanism_of_action': 'Fully elucidated',
                'target_validation': 'In vitro + in vivo',
                'pharmacodynamics': 'Biomarker response',
                'dose_response': '3-4 dose levels minimum',
            },
            'pharmacokinetics': {
                'adme': 'Rat and dog required',
                'absorption': 'Oral bioavailability',
                'distribution': 'Tissue distribution',
                'metabolism': 'Metabolite identification',
                'excretion': 'Urinary + fecal recovery',
                'drug_interactions': 'CYP450 profile',
            },
            'microbiology': {
                'antimicrobial_properties': 'If applicable',
                'resistance_potential': 'If antibacterial',
            },
        }

    def _load_pediatric_standards(self) -> Dict:
        """Load pediatric-specific standards."""
        return {
            'safety_margins': {
                'neonatal': 10.0,  # 10x safety margin minimum
                'infant': 5.0,
                'toddler': 3.0,
                'child': 2.0,
                'adolescent': 1.5,
            },
            'formulation_requirements': {
                'taste': 'Acceptable to children',
                'volume': 'Swallowable (max 5mL)',
                'frequency': 'Convenient (daily preferred)',
                'storage': 'Room temperature ideal',
                'shelf_life': '24+ months',
            },
            'efficacy_endpoints': {
                'primary': 'Clinical benefit (complete/partial response)',
                'secondary': 'Overall survival, disease-free survival',
                'surrogate': 'Biomarker response, imaging',
            },
            'monitoring': {
                'organ_toxicity': 'Organ-specific thresholds',
                'growth': 'Height/weight curves',
                'development': 'Neurodevelopmental assessment',
                'quality_of_life': 'Age-appropriate scales',
            },
        }

    def design_biochemical_validation(
        self,
        compound_id: str,
        target_protein: str,
        predicted_affinity: float,
    ) -> List[BiochemicalAssay]:
        """Design biochemical assay battery.

        Args:
            compound_id: e.g., 'AGI-PYRENE3-0001'
            target_protein: e.g., 'BCL2'
            predicted_affinity: e.g., -9.4 kcal/mol

        Returns:
            List of planned biochemical assays
        """

        assays = []

        # Convert affinity to Kd (nanomolar)
        # -9.4 kcal/mol ≈ 0.1-1 µM ≈ 100-1000 nM
        predicted_kd = self._convert_affinity_to_kd(predicted_affinity)

        # SPR - Real-time kinetics (on/off rates)
        sprt_assay = BiochemicalAssay(
            assay_id=f"{compound_id}-SPR",
            compound_id=compound_id,
            target_protein=target_protein,
            method='SPR',
            predicted_kd=predicted_kd,
            confidence=0.85,
            expected_duration='2-3 days',
            resource_requirements={
                'instrument': 'Biacore T200',
                'cost': '$2,000-3,000',
                'sample_requirement': '50-100 µg',
                'temperature': '25°C (physiological if needed)',
                'measures': ['kon', 'koff', 'Kd'],
            }
        )
        assays.append(sprt_assay)

        # ITC - Thermodynamics (∆H, ∆S, ∆G)
        itc_assay = BiochemicalAssay(
            assay_id=f"{compound_id}-ITC",
            compound_id=compound_id,
            target_protein=target_protein,
            method='ITC',
            predicted_kd=predicted_kd * 0.9,  # Usually gives slightly better Kd
            confidence=0.90,
            expected_duration='1-2 days',
            resource_requirements={
                'instrument': 'Malvern MicroCal iTC200',
                'cost': '$1,500-2,000',
                'sample_requirement': '100-200 µg protein',
                'temperature': '25°C or 37°C (pediatric)',
                'measures': ['Kd', 'ΔH', 'ΔS', 'n (stoichiometry)'],
            }
        )
        assays.append(itc_assay)

        # Fluorescence Polarization - High-throughput
        flp_assay = BiochemicalAssay(
            assay_id=f"{compound_id}-FP",
            compound_id=compound_id,
            target_protein=target_protein,
            method='FluorPol',
            predicted_kd=predicted_kd * 1.2,  # Typically slightly weaker
            confidence=0.80,
            expected_duration='2-3 days',
            resource_requirements={
                'instrument': 'Tecan Infinity',
                'cost': '$500-1,000',
                'sample_requirement': '10-50 µg',
                'temperature': 'Room temperature',
                'measures': ['Kd (IC50 conversion)'],
                'throughput': '384-well format',
            }
        )
        assays.append(flp_assay)

        # HTRF - Time-resolved fluorescence
        htrf_assay = BiochemicalAssay(
            assay_id=f"{compound_id}-HTRF",
            compound_id=compound_id,
            target_protein=target_protein,
            method='HTRF',
            predicted_kd=predicted_kd,
            confidence=0.82,
            expected_duration='1-2 days',
            resource_requirements={
                'instrument': 'Envision or Cytation',
                'cost': '$300-500',
                'sample_requirement': '5-20 µg',
                'temperature': 'Room temperature',
                'measures': ['TR-FRET ratio', 'Kd'],
                'throughput': '384-well, automation-friendly',
            }
        )
        assays.append(htrf_assay)

        return assays

    def _convert_affinity_to_kd(self, binding_energy: float) -> float:
        """Convert binding energy (kcal/mol) to Kd (nM).

        Using: ΔG = -RT ln(1/Kd)
        """
        import math

        R = 1.987e-3  # kcal/mol·K
        T = 298.15    # 25°C in Kelvin

        # ΔG = binding_energy
        # Kd = exp(ΔG / RT)

        kd_m = math.exp(binding_energy / (R * T))
        kd_nm = kd_m * 1e9

        return max(kd_nm, 1.0)  # Minimum 1 nM

    def design_cell_assays(
        self,
        compound_id: str,
        mechanism: str,
        target_protein: str,
    ) -> List[CellAssay]:
        """Design cell-based apoptosis assay battery.

        Args:
            compound_id: e.g., 'AGI-PYRENE3-0001'
            mechanism: e.g., 'INTRINSIC'
            target_protein: e.g., 'BCL2'

        Returns:
            List of planned cell assays
        """

        assays = []

        # Select appropriate cell lines by mechanism
        cell_line_map = {
            'INTRINSIC': [CellLine.RAJI, CellLine.JURKAT],  # BCL2-dependent
            'EXTRINSIC': [CellLine.JURKAT, CellLine.MOLT4],  # FAS-dependent
            'ANTI_APOPTOTIC': [CellLine.U937, CellLine.MOLT4],  # IAP-dependent
            'HYBRID': [CellLine.HEK293, CellLine.U937],  # General apoptosis
        }

        cell_lines = cell_line_map.get(mechanism, [CellLine.U937])

        for cell_line in cell_lines:
            # Caspase-3 activation (early apoptosis)
            casp3_assay = CellAssay(
                assay_id=f"{compound_id}-Casp3-{cell_line.value}",
                compound_id=compound_id,
                mechanism=mechanism,
                cell_line=cell_line.value,
                apoptosis_readout='Caspase-3/7 activation',
                expected_ec50=100,  # nM
                expected_efficacy=80.0,  # 80% apoptotic cells at 10µM
                duration_hours=4,  # Fast kinetics
                animal_ethics=False,
            )
            assays.append(casp3_assay)

            # Annexin V / PI staining (late apoptosis)
            annv_assay = CellAssay(
                assay_id=f"{compound_id}-AnnV-{cell_line.value}",
                compound_id=compound_id,
                mechanism=mechanism,
                cell_line=cell_line.value,
                apoptosis_readout='Annexin V+/PI- (early) and PI+ (late)',
                expected_ec50=150,  # nM
                expected_efficacy=75.0,  # 75% apoptotic at 10µM
                duration_hours=6,
                animal_ethics=False,
            )
            assays.append(annv_assay)

            # TMRM staining (mitochondrial depolarization - INTRINSIC only)
            if mechanism == 'INTRINSIC':
                tmrm_assay = CellAssay(
                    assay_id=f"{compound_id}-TMRM-{cell_line.value}",
                    compound_id=compound_id,
                    mechanism=mechanism,
                    cell_line=cell_line.value,
                    apoptosis_readout='TMRM fluorescence loss (ΔΨm)',
                    expected_ec50=80,  # nM
                    expected_efficacy=70.0,  # 70% loss of ΔΨm
                    duration_hours=3,
                    animal_ethics=False,
                )
                assays.append(tmrm_assay)

        return assays

    def design_selectivity_panel(
        self,
        compound_id: str,
        primary_target: str,
        mechanism: str,
    ) -> SelectivityScreen:
        """Design selectivity screening panel.

        Args:
            compound_id: e.g., 'AGI-PYRENE3-0001'
            primary_target: e.g., 'BCL2'
            mechanism: e.g., 'INTRINSIC'

        Returns:
            Selectivity screen design
        """

        # Target-specific selectivity panels
        selectivity_maps = {
            'BCL2': {
                'priority_targets': [
                    'BCL-xL', 'MCL1', 'BCL-w', 'BFL1', 'A1',  # Other anti-apoptotic
                    'BAX', 'BAK', 'BID',  # Pro-apoptotic (avoid)
                    'XIAP', 'cIAP1', 'cIAP2', 'survivin',  # Off-target
                    'ERG', 'FOXM1', 'E2F1',  # Transcription factors
                    'HSP90', 'MDM2', 'TP53',  # Other oncology targets
                ],
                'concern_flags': [
                    'XIAP_cross_reactivity',
                    'BAX_binding_undesired',
                    'protein_stability_effects',
                ],
            },
            'FAS': {
                'priority_targets': [
                    'TNFR1', 'TNFR2', 'TNF',  # Related death receptors
                    'CASPASE8', 'CASPASE10',  # Signaling cascade
                    'FADD', 'cFLIP',  # Adaptor proteins
                    'ERK1/2', 'p38', 'JNK',  # MAPK (cross-reactivity risk)
                ],
                'concern_flags': [
                    'systemic_inflammation_risk',
                    'hepatotoxicity_from_FAS',
                    'autoimmune_activation',
                ],
            },
            'XIAP': {
                'priority_targets': [
                    'cIAP1', 'cIAP2', 'survivin', 'livin', 'BRUCE',  # IAP family
                    'CASPASE3', 'CASPASE7', 'CASPASE9',  # Caspases (avoid direct hit)
                    'TNF', 'TNFR1', 'TNFR2',  # Sensitizers
                    'NF-kB', 'IKK', 'NEMO',  # Inflammation pathway
                ],
                'concern_flags': [
                    'caspase_direct_inhibition',
                    'nfkb_off_target_activation',
                    'systemic_tnf_release_risk',
                ],
            },
        }

        panel = selectivity_maps.get(primary_target, {
            'priority_targets': [
                'related_targets_by_mechanism',
                'common_off_targets',
                'kinase_panel_if_applicable',
            ],
            'concern_flags': [],
        })

        screen = SelectivityScreen(
            screen_id=f"{compound_id}-SEL",
            compound_id=compound_id,
            panel_size=len(panel['priority_targets']),
            priority_targets=panel['priority_targets'],
            expected_selectivity_ratio=100.0,  # 100:1 desired
            concern_flags=panel['concern_flags'],
        )

        return screen

    def design_pediatric_formulation(
        self,
        compound_id: str,
        target_age_group: str,
        predicted_potency: float,
    ) -> FormulationStrategy:
        """Design pediatric-optimized formulation.

        Args:
            compound_id: e.g., 'AGI-PYRENE3-0001'
            target_age_group: e.g., 'toddler', 'child', 'adolescent'
            predicted_potency: binding energy in kcal/mol

        Returns:
            Formulation strategy
        """

        # Age-group specific formulation parameters
        formulation_map = {
            'neonatal': {
                'form': 'IV infusion or suspension',
                'volume': 1.0,  # mL per dose
                'taste_mask': False,
                'frequency': '3-4x daily',
                'stability': 'Refrigerated',
            },
            'infant': {
                'form': 'Liquid suspension',
                'volume': 2.0,  # mL
                'taste_mask': True,
                'frequency': '2x daily',
                'stability': 'Room temperature acceptable',
            },
            'toddler': {
                'form': 'Oral liquid or small capsule',
                'volume': 3.0,  # mL if liquid
                'taste_mask': True,
                'frequency': '2x daily',
                'stability': 'Room temperature',
            },
            'child': {
                'form': 'Tablet/capsule or liquid',
                'volume': 5.0,  # mL if liquid (max swallowable)
                'taste_mask': True,
                'frequency': 'Once or twice daily',
                'stability': 'Room temperature',
            },
            'adolescent': {
                'form': 'Standard tablet/capsule',
                'volume': 0.0,  # Solid dosage
                'taste_mask': False,
                'frequency': 'Once daily preferred',
                'stability': 'Room temperature',
            },
        }

        formulation_params = formulation_map.get(target_age_group, formulation_map['child'])

        # Calculate expected dose based on potency
        # Assume 1-2 mg/kg for strong binders like BCL2 inhibitors
        dose_mg_per_kg = 1.0 if predicted_potency < -9.0 else 2.0

        strategy = FormulationStrategy(
            compound_id=compound_id,
            formulation_type=formulation_params['form'],
            target_age_group=target_age_group,
            volume_per_dose=formulation_params['volume'],
            taste_masking=formulation_params['taste_mask'],
            stability_requirement=formulation_params['stability'],
            excipient_safety=0.95,  # High for pediatric-approved excipients
        )

        return strategy

    def generate_ind_enabling_studies_plan(
        self,
        compound_id: str,
        target_protein: str,
        target_indication: str,
        compound_class: str = 'small_molecule',
    ) -> Dict:
        """Generate complete IND-enabling studies plan.

        Args:
            compound_id: e.g., 'AGI-PYRENE3-0001'
            target_protein: e.g., 'BCL2'
            target_indication: e.g., 'pediatric_lymphoma'
            compound_class: e.g., 'small_molecule'

        Returns:
            Complete IND-enabling studies plan
        """

        plan = {
            'compound_id': compound_id,
            'target': target_protein,
            'indication': target_indication,
            'timeline_months': 12,
            'estimated_cost': '$2M-3M',

            'chemistry_manufacturing_controls': {
                'priority': 'IMMEDIATE',
                'studies': [
                    'Synthetic route optimization & scale-up',
                    'NMR, MS, HPLC characterization',
                    'Purity determination (>98% required)',
                    'Stability: 6-month accelerated + 9-month long-term',
                    'Impurity identification & qualification',
                    'Manufacturing process validation (3 batches)',
                ],
                'deliverables': [
                    'CMC section for IND',
                    'Certificate of Analysis',
                    'Stability protocol & data',
                    'Manufacturing validation report',
                ],
                'timeline': '4-6 months',
            },

            'pharmacology_primary': {
                'priority': 'IMMEDIATE',
                'studies': [
                    'Mechanism of action (biochemical)',
                    'Target binding studies (SPR, ITC, FP)',
                    'Target selectivity panel (15-20 off-targets)',
                    'Cellular apoptosis assays',
                    'Target engagement in cells (CETSA)',
                    'Gene expression profiling (DNA array)',
                ],
                'deliverables': [
                    'Pharmacology IND section',
                    'Target validation data',
                    'Selectivity profile',
                    'Mechanism report',
                ],
                'timeline': '3-4 months',
            },

            'pharmacokinetics_adme': {
                'priority': 'IMMEDIATE',
                'studies': [
                    'In vitro ADME (microsomal, hepatocyte metabolism)',
                    'CYP450 inhibition & induction (5 major CYPs)',
                    'Plasma protein binding',
                    'Rat PK (IV & oral) - 3-4 animals',
                    'Dog PK (IV & oral) - 4-6 animals',
                    'TK in toxicology studies (embedded)',
                    'ADME/radiolabel study (rat, optional)',
                ],
                'deliverables': [
                    'PK/ADME IND section',
                    'CYP interaction table',
                    'Bioavailability assessment',
                    'Drug-drug interaction risk',
                ],
                'timeline': '4-5 months',
            },

            'toxicology': {
                'priority': 'IMMEDIATE',
                'studies': [
                    'In vitro (3T3 NRU, AMES, micronucleus)',
                    'Acute tox (limit dose study, rat)',
                    '14-day tox (rat) - 3 dose levels + controls',
                    '28-day tox (dog) - 3 dose levels + controls',
                    'Target organ identification',
                    'Reversibility assessment (14-day recovery)',
                    'Special studies (as indicated by findings)',
                ],
                'deliverables': [
                    'Toxicology IND section',
                    'No observed adverse effect level (NOAEL)',
                    'Maximum tolerated dose (MTD)',
                    'Safety margins assessment',
                    'Target organ discussion',
                ],
                'timeline': '5-6 months',
            },

            'pediatric_specific': {
                'priority': 'HIGH',
                'studies': [
                    'Formulation development (pediatric-appropriate)',
                    'Taste-masking validation (if liquid)',
                    'Stability at pediatric storage conditions',
                    'Dissolution profile (if tablet/capsule)',
                    'Bioavailability in pediatric surrogates (if possible)',
                    'Age-specific safety margins verification',
                ],
                'deliverables': [
                    'Pediatric formulation dossier',
                    'Stability data at multiple temperatures',
                    'Proposed pediatric dosing strategy',
                    'Safety monitoring plan for pediatrics',
                ],
                'timeline': '4-5 months',
            },

            'clinical_pharmacology': {
                'priority': 'BEFORE_FIRST_IN_HUMAN',
                'studies': [
                    'Human PK population PK/PD modeling',
                    'Dose escalation strategy design',
                    'Drug-drug interaction studies (if needed)',
                    'Special population studies (hepatic/renal)',
                    'Biomarker validation in clinic',
                ],
                'timeline': 'During IND (Phase 0/I)',
            },

            'regulatory_requirements': [
                'Form IND (1571)',
                'CMC module',
                'Pharmacology & Toxicology modules',
                'Previous human experience (if applicable)',
                'Pediatric study plan (PSP) addendum',
                'Financial disclosures (Form 3454/3455)',
            ],

            'go_no_go_decision_points': [
                'Month 3: Pharmacology sufficiently demonstrates mechanism',
                'Month 4: Early tox shows acceptable safety profile',
                'Month 6: CMC sufficient for IND manufacturing',
                'Month 8: Complete nonclinical package acceptable',
                'Month 12: IND filing decision',
            ],

            'anticipated_timeline': {
                'CMC': '4-6 months',
                'Pharmacology': '3-4 months',
                'ADME/PK': '4-5 months',
                'Toxicology': '5-6 months',
                'Pediatric formulation': '4-5 months',
                'Regulatory preparation': '1-2 months',
                'Total (with overlap)': '12-14 months',
            },
        }

        return plan

    def create_validation_report(
        self,
        compound_id: str,
        biochemical_assays: List[BiochemicalAssay],
        cell_assays: List[CellAssay],
        selectivity_screen: SelectivityScreen,
        formulation: FormulationStrategy,
    ) -> Dict:
        """Create comprehensive validation report.

        Args:
            compound_id: e.g., 'AGI-PYRENE3-0001'
            biochemical_assays: List of planned biochemical assays
            cell_assays: List of planned cell assays
            selectivity_screen: Selectivity screening design
            formulation: Pediatric formulation strategy

        Returns:
            Complete validation report for publication/IND
        """

        report = {
            'compound_id': compound_id,
            'report_date': '2026-09-19',
            'status': 'Experimental Validation Plan',

            'executive_summary': f"""
Comprehensive validation plan for {compound_id}:
- {len(biochemical_assays)} biochemical assays planned
- {len(cell_assays)} cell-based apoptosis assays planned
- {selectivity_screen.panel_size}-member selectivity panel
- Pediatric-optimized formulation (target: {formulation.target_age_group})
- Full IND-enabling studies program (12-14 month timeline)
            """.strip(),

            'biochemical_validation': {
                'assays': [
                    {
                        'method': a.method,
                        'predicted_kd': f"{a.predicted_kd:.1f} nM",
                        'confidence': f"{a.confidence:.0%}",
                        'duration': a.expected_duration,
                        'cost': a.resource_requirements.get('cost', 'N/A'),
                        'measures': a.resource_requirements.get('measures', []),
                    }
                    for a in biochemical_assays
                ]
            },

            'cellular_validation': {
                'assays': [
                    {
                        'cell_line': a.cell_line,
                        'mechanism': a.mechanism,
                        'readout': a.apoptosis_readout,
                        'expected_ec50': f"{a.expected_ec50} nM",
                        'expected_efficacy': f"{a.expected_efficacy:.0f}%",
                        'duration': f"{a.duration_hours}h",
                    }
                    for a in cell_assays[:3]  # Show top 3
                ]
            },

            'selectivity_assessment': {
                'panel_size': selectivity_screen.panel_size,
                'priority_targets': selectivity_screen.priority_targets[:5],
                'concern_flags': selectivity_screen.concern_flags,
                'expected_selectivity_ratio': f"{selectivity_screen.expected_selectivity_ratio:.0f}:1",
            },

            'pediatric_formulation': {
                'formulation_type': formulation.formulation_type,
                'target_age_group': formulation.target_age_group,
                'volume_per_dose': f"{formulation.volume_per_dose} mL",
                'taste_masking': formulation.taste_masking,
                'storage': formulation.stability_requirement,
                'safety_score': f"{formulation.excipient_safety:.0%}",
            },
        }

        return report

class ExperimentalTimeline:
    """Manages experimental validation timeline."""

    def __init__(self):
        self.phases = {}

    def create_timeline(
        self,
        compound_id: str,
        num_compounds: int,
    ) -> Dict:
        """Create realistic experimental timeline.

        Args:
            compound_id: Lead compound ID
            num_compounds: Number of backup compounds

        Returns:
            Full experimental timeline with milestones
        """

        return {
            'lead_compound': compound_id,
            'backup_compounds': num_compounds - 1,

            'phase_0_lead_characterization': {
                'duration': 'Week 1-4',
                'activities': [
                    'Confirm structure (NMR, MS, HPLC)',
                    'Purity assessment (HPLC)',
                    'Stability screening (3 conditions)',
                    'Solubility testing',
                ],
                'deliverables': [
                    'Certificate of Analysis',
                    'Preliminary stability data',
                    'Formulation feasibility assessment',
                ],
            },

            'phase_1_biochemical_validation': {
                'duration': 'Week 4-12 (parallel with Phase 0)',
                'activities': [
                    'SPR kinetics (kon, koff, Kd)',
                    'ITC thermodynamics (ΔH, ΔS, ΔG)',
                    'Fluorescence polarization (IC50)',
                    'HTRF assay (high-throughput)',
                ],
                'deliverables': [
                    'Binding affinity confirmation',
                    'Target engagement data',
                    'Mechanistic insights',
                ],
                'success_criteria': 'Kd ≤ 500 nM by multiple methods',
            },

            'phase_2_selectivity_screening': {
                'duration': 'Week 8-16',
                'activities': [
                    'Panel testing (15-20 off-targets)',
                    'Selectivity ratio calculation',
                    'Cross-reactivity identification',
                    'Risk assessment',
                ],
                'deliverables': [
                    'Selectivity profile (100:1+ ratio desired)',
                    'Off-target toxicity risk assessment',
                    'Mechanism-based inhibition screening',
                ],
                'success_criteria': 'Selectivity ratio ≥100:1 primary/off-targets',
            },

            'phase_3_cell_based_validation': {
                'duration': 'Week 12-20 (parallel)',
                'activities': [
                    'Apoptosis assays (Caspase-3, Annexin V)',
                    'Mitochondrial depolarization (TMRM)',
                    'Cell line panel testing',
                    'Dose-response curves',
                    'Mechanism confirmation',
                ],
                'deliverables': [
                    'EC50 values in relevant cell lines',
                    'Apoptosis efficacy data',
                    'Mechanism validation in cells',
                ],
                'success_criteria': 'EC50 ≤ 200 nM, efficacy ≥70% at 10µM',
            },

            'phase_4_formulation_development': {
                'duration': 'Week 16-24',
                'activities': [
                    'Formulation screening (solubility, stability)',
                    'Pediatric formulation selection',
                    'Taste-masking optimization',
                    'Stability testing (accelerated)',
                    'Bioavailability prediction',
                ],
                'deliverables': [
                    'Optimal formulation identified',
                    '6-month accelerated stability data',
                    'Bioavailability assessment',
                    'Pediatric dosing proposal',
                ],
                'success_criteria': '>80% oral bioavailability, stable 6+ months',
            },

            'phase_5_ind_enabling_studies': {
                'duration': 'Week 20-56 (12-14 months total)',
                'parallel_activities': {
                    'CMC': 'Synthetic scale-up, purity, stability',
                    'Pharmacology': 'Target engagement, selectivity, mechanism',
                    'ADME': 'Rat & dog PK, CYP interactions, protein binding',
                    'Toxicology': 'In vitro + acute + subchronic (14/28-day)',
                    'Pediatric': 'Formulation, dosing strategy, safety margins',
                },
                'deliverables': [
                    'IND-enabling package (CMC + Tox + Pharm)',
                    'Pediatric study plan addendum',
                    'Safety analysis & margins',
                    'Clinical pharmacology plan',
                ],
                'success_criteria': 'FDA accepts IND for clinical trial initiation',
            },

            'key_milestones': [
                'Month 1: Lead confirmed in biochemical assays',
                'Month 2: Selectivity screen complete, no major concerns',
                'Month 3: Cell assays validate mechanism, EC50 <200nM',
                'Month 4: Formulation selected, bioavailability confirmed',
                'Month 6: CMC & initial tox data acceptable',
                'Month 12: Complete IND-enabling package ready',
                'Month 12-14: IND filing with FDA',
            ],

            'go_no_go_triggers': [
                'Biochemical: If Kd >1µM, deprioritize',
                'Selectivity: If ratio <10:1, reassess mechanism',
                'Cells: If EC50 >1µM, formulation unlikely to help',
                'Tox: If NOAEL <30x target therapeutic dose, reconsider',
                'Pediatric: If formulation unpalatable, major issue',
            ],
        }
